file copy

Form PTO-1449 (Rev. 2-32) Atty. Docket No.: Serial No.: U.S. Department of Commerce Q-59836 09/599,002 Patent & Trademark Office INFORMATION DISCLOSURE STATEMENT Applicant: (Use several sheets if necessary) ${\tt Harold\ I.\ \underline{NYLAND\ et\ al}}$ Filing Date: Group: 1655 June 22, 2000 Conf. No.: 8578 U.S. PATENT DOCUMENTS Examiner In Ptial Document Date Name Class Sub-Filing Date Number Class (if appropriate) NOV 0 9 2001 FOREIGN PATENT DOCUMENTS Document Date Country Class Sub-Translation class Yes/No 96/06952 WO 03/07/96 PCT WO 97/46715 12/11/97 PCT WO 95/05481 02/23/95 PCT 97/08338 WO 03/06/97 PCT 12/22/94 WO 94/29351 PCT OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Rascu et al, Ann. New York Acad. Sci., 815:282-295 (1997) Wu et al, J. Clin. Invest., <u>100(5)</u>:1059-1070 (1997) Deo et al, *Immunol*. *Today*, <u>18(3)</u>:127-134 (1997) Oldstone et al, Scand. J. Immunol., <u>46</u>:320-325 (1997) Conti et al, J. Neurology, 244(3):565 (1997) Vedeler et al, Acta Path. Microbiol. Immunol. Scand., Section C., <u>92</u>:133-137 (1984) The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group, Neurology, <u>45(7)</u>:1277-1285 (1995) Platonov et al, Clin. Exp. Immunol., 111:97-101 (1998) Ohany DATE CONSIDERED: EXAMINER: 1) and B EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication.